Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update.

Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update. Eur J Cancer. 2018 05; 94:115-125.

View in: PubMed

subject areas

Aged
Anilides
Antineoplastic Agents
Carcinoma, Renal Cell
Female
Humans
Kaplan-Meier Estimate
Kidney Neoplasms
Male
Middle Aged
Proportional Hazards Models
Pyridines

authors with profiles

Olwen Hahn